Respiratory virus vaccines - to dominate industry focus


25-01-2021
lung x rays

This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand new analysis focused on the respiratory virus vaccine segment to 2035. Seven new potential vaccine products are covered.

For the top four Western vaccine manufacturers, the market for respiratory virus vaccines (mostly due seasonal influenza) was worth an estimated ~$3.8bn in FY 2019 ranked third in terms of value behind pediatric and pneumococcal vaccines. With the emergence of the COVID-19 [SARS-CoV-2] global pandemic in early 2020 and the rapid development of new vaccines, VacZine Analytics believes respiratory virus vaccines segment will soon dominate global industry revenues becoming the leading segment in 2021. The status quo will alter with new players, new technologies and a renewed focus on other respiratory pathogens.

Even before the pandemic, lower respiratory tract infections (LRTIs), due to all causes, were a leading cause of morbidity and mortality globally with an estimated 2.3m deaths (GBD, 2016). LRTIs are the sixth leading cause of mortality worldwide (all ages) and the leading cause of death in children younger than 5 years (2018 figures). In the best case, the mortality exerted by LRTIs has doubled due to the SARS-CoV-2 coronavirus pandemic which has already caused ~2.1m deaths (CSSE, JHU as of 25th January 2021). Limiting future mortality is now critically dependent on the speed of deployment and the real-world effectiveness of global mass vaccination campaigns. Virological parameters, such as genetic variation, the duration of vaccine-induced immunity and impact on transmission are important (as yet undefined) variables.

This brand new Respiratory virus vaccines report looks collectively at this overall market segment and covers 7 important respiratory pathogens including viruses such as seasonal influenza, Respiratory Syncytial Virus (RSV), SARS-CoV-2 [pandemic/seasonal], human metapneumovirus/PIV3 and others which will continue to dominate manufacturer R&D focus over the coming years. The report contains a comparative discussion of the global disease burden exerted by these pathogens, vaccine profiles (TPPs) with all relevant commercial assumptions, competitive dynamics and POS/Non-POS adjusted new vaccine revenue ($ 000s) forecasts per region (USA and Major 5 EU) to 2035. New product development is a report focus with an emphasis on mRNA candidates and marketing strategy. It is an ideal analysis for those wishing to understand the key issues and longer-term outlook for this important vaccine market segment.

VacZine Analytics is a strategic research agency based in the United Kingdom since 2007. We aim to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit the website www.vaczine-analytics.com

 or contact mailto:info@vaczine-analytics.com

VacZine Analytics® is a trading division of Assay Advantage Ltd, UK Company No. 5807728

Image: CDC, available on unsplash

Copyright. All Rights Reserved, 2021

 

VacZine Analytics is an established strategic research publisher based in the United Kingdom.

VacZine Analytics Ltd (Assay Advantage)